Evidence map›Paper›PMID 19830694›Full record

ArticleInternational journal of cancer2010

EGFR variant-mediated invasion by enhanced CXCR4 expression through transcriptional and post-translational mechanisms.

Massod Rahimi, Jessica George, Careen Tang

Open access · bronzeAbstract read
In one paragraph

Article in International journal of cancer, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Oncogenic roles and drug target of CXCR4/CXCL12 axis in lung cancer and cancer stem cell.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016
    Review
  7. CXCR4 in breast cancer: oncogenic role and therapeutic targeting.Drug design, development and therapy · 2015
    Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Massod RahimiDepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington DC.
Jessica GeorgeDepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington DC.
Careen TangDepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington DC.
Georgetown University Medical Center · USGeorgetown University · US

Funding

Tissue Culture Shared ResourceP30CA051008 · NCI · GEORGETOWN UNIVERSITY · PI STEPHEN W BYERS · 1990 to 2026
$71.5M
Coexpression of EGFRvlll/ErbB2 in Human Breast CancerR01CA088871 · NCI · GEORGETOWN UNIVERSITY · PI TANG, CAREEN K · 2001 to 2005
$1.3M
Molecular Mechanisms of Blockage of ErbB receptorsR01CA106429 · NCI · GEORGETOWN UNIVERSITY · PI TANG, CAREEN K · 2005 to 2009
$1.2M
NCI NIH HHS 1P30CA51008NCI NIH HHS P30 CA051008NCI NIH HHS R01 CA088871NCI NIH HHS R01 CA106429NCI NIH HHS R01CA106429NCI NIH HHS R01CA88871
6 · The paper itself

Abstract

The expression of the potent, constitutively activated EGFR variant, EGFRvIII, has been linked to breast cancer metastasis, but the mechanisms of EGFRvIII and CXCR4 crosstalk, which may facilitate breast cancer invasion, have never been explored. Here we report that CXCR4 expression is increased in breast cancer cells expressing EGFRvIII regardless of the ER/PgR status of the cells. Treatment of EGFRvIII-expressing breast cancer cells with the tyrosine kinase inhibitor, AG1478, reverses CXCR4 expression back to levels expressed in parental cells. In addition, expressing EGFRvIII enhances CXCL12/CXCR4-mediated invasion, which can be inhibited by CXCR4 inhibitors. Surprisingly, CXCR4 mRNA and its transcriptional regulator, HIF-1alpha, are up-regulated only in ER+/PgR+ estrogen-dependent EGFRvIII-expressing breast cancer cells, but not in ER-/PgR- or estrogen-independent cell lines, suggesting that HIF-1alpha and hormone receptor-mediated actions may have a role in the transcriptional regulation of CXCR4. We also demonstrate that p38 MAPK is one of the major down-stream signaling molecules responsible for EGFRvIII/CXCR4-mediated invasion as p38 MAPK activity was induced by CXCL12 stimulation under both normoxic and hypoxic conditions. More interestingly, inhibition of p38 MAPK activity significantly reduced CXCR4 expression and inhibited the invasive potential of EGFRvIII-expressing breast cancer cells, suggesting an essential role for p38 MAPK in EGFRvIII/CXCR4 induced invasion. Furthermore, CXCR4 is regulated post-translationally through decreased expression of AIP4 and beta-arrestin 1/2, molecules involved in CXCR4 internalization, cellular trafficking and degradation. These results provide a plausible mechanism for EGFRvIII-mediated invasion and establish a functional link between EGFRvIII and CXCR4 signaling pathways.

Indexed as

Gene Expression Regulation, NeoplasticAnimalsBreast NeoplasmsCell Line, TumorCell SeparationErbB ReceptorsFemaleFlow CytometryGene ExpressionHumansImmunoblottingMiceNeoplasm InvasivenessProtein IsoformsProtein Processing, Post-TranslationalReceptors, CXCR4CXCR4 protein, humanErbB ReceptorsProtein IsoformsReceptors, CXCR4

Identifiers

PMID19830694
PMCPMC2917067
OpenAlexW2041910525

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.